Quality Control Guidelines for Clinical-Grade Human Induced Pluripotent Stem Cell Lines
About the Speakers
Dr. Stephen Sullivan is a program manager at the Global Alliance for iPSC Therapies (GAiT). Since 2017, Dr Sullivan has overseen operations at GAiT, supporting implementation and clinical application of therapies derived from pluripotent stem cells for the benefit of patients globally.
Dr. Andrew Gaffney completed his PhD in Pediatric Oncology from the University of Leeds, UK, where he successfully established a human embryonic stem cell disease model of Ewing’s sarcoma. Currently, Andrew works closely with renowned stem cell scientists in both industry and academia to monitor the requirements needed for establishing successful hPSC-based disease models, drug screens, and cell therapy applications, as part of STEMCELL’s Strategic Alliances.
Related Multimedia
-
Qualification of Ancillary/Raw Materials for Clinical Use
Publish Date: June 20, 2018 -
Improving Reproducibility of Your hPSC Research by Generating a High-Quality Cell Bank
Publish Date: May 27, 2020 -
Considerations for High-Efficiency Genome Editing of Human Pluripotent Stem Cells
Publish Date: May 29, 2020
Explore Our Products
-
STEMdiff™ Trilineage Differentiation Kit
Functional assay kit to assess pluripotency by directed differentiation of human ES and iPS cells to all three germ layers -
qPCR analysis kit for detecting the majority of karyotypic abnormalities reported in human ES and iPS cells